

Volume 37, Number 1 (Supplement) September 2017

ISSN 0333-1024 (Print)
ISSN 1468-2982 (Online)

Cephalalgia

An International Journal of Headache

Abstracts of the 18th International Headache Congress

International Headache Society
7–10 September 2017
Vancouver Convention Centre
Canada



International
Headache Society

www.ihs-headache.org
journals.sagepub.com/home/cep





healthdocbox.com is now full screen

Exit Full Screen (Esc)

Editor-in-Chief, *Arne May, Germany*

Previous Editors, Ottar Sjaastad (Founding Editor), Marcia Wilkinson, K Michael Welch, Peter J Goadsby, David W Dodick

Managing Editor, Wendy Krank
Email: editorial.cephalgia@gmail.com

Associate Editors

Frank Andrasik, USA
Messoud Ashina, Denmark
Rafael Benoliel, USA
Rami Burstein, USA
Andrew Charles, USA
Hans-Christoph Diener, Germany
Anne Ducros, France
Lars Edvinsson, Sweden
Stefan Evers, Germany
Michel D Ferrari, Netherlands
Edith Hamel, Canada
Andrew Hershey, USA
Phillip R Holland, UK
Elizabeth Loder, USA
Arn van den Maagdenberg, Netherlands
Delphine Magis, Belgium
Karl Messlinger, Germany
Frank Porreca, USA
Michael B Russell, Norway
Ann Scher, USA
Todd Schwedt, USA
Gisela Terwindt, Netherlands
Shuu-Jiun Wang, Taiwan
Alessandro Zagami, Australia

Junior Editors

Larus S Gudmundsson, Iceland
Andrea Harriott, USA
Jan R Hoffmann, Germany

Biostatistics Editors, Richard Chiacchierini and Jayawant Mandrekar

Book Reviews Editor, Richard Peatfield

Historical Section Editor, Peter J Koehler

Ombudsman, David W Dodick

Publishing and Scientific Integrity Advisor, Peter J Goadsby



SAGE is a member of CrossRef.

Abstracting and indexing

Please visit cep.sagepub.com and click on the Abstracting/Indexing link on the left hand side to view a full list of databases in which this journal is indexed.

Subscriptions and advertising

Cephalgia (ISSN: 0333-1024 print, 1468-2982 online) is published 14 times a year by SAGE Publications Ltd (Los Angeles, London, New Delhi, Singapore, Washington DC and Melbourne).

The US annual subscription price is [\$2539]. Airfreight and mailing in the USA by agent Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Jamaica NY 11431. US Postmaster: Send address changes to *Cephalgia*, Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Subscription records are maintained at SAGE Publications Ltd, 1 Oliver's Yard, 55 City Road, London EC1Y 1SP, UK. Air Business Ltd is acting as our mailing agent.

Annual subscription (2017) including postage: Combined Institutional Rate (print and electronic) [£1274/US\$2539]. Electronic only and print only subscriptions are available for institutions at a discounted rate. Note VAT is applicable at the appropriate local rate. Visit sagepublishing.com for more details including individual rates, single-copy rates and pay per view. Abstracts, tables of contents and contents alerts are available online free of charge for all. Further details are available from SAGE Publications Ltd, 1 Oliver's Yard, 55 City Road, London EC1Y 1SP, UK, tel. +44 (0)20 7324 8500, email subscriptions@sagepub.co.uk, and in North America, SAGE Publications Inc, PO Box 5096, Thousand Oaks, CA 91320, USA.

Commercial Sales

For information on advertising, reprints and supplements please contact Tamara Haq, tamara.haq@sagepub.co.uk

Copyright

© International Headache Society 2017

Apart from fair dealing for the purposes of research or private study, or criticism or review, and only as permitted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the Publishers, or in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency or your equivalent national blanket licensing agency. Enquiries concerning reproduction outside of those terms should be sent to SAGE.

Disclaimer

The authors, editors, and publisher will not accept any legal responsibility for any errors or omissions that may be made in this publication. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper by Page Bros, Norwich, UK



1.1 hrs). ALD403 was well-tolerated with no serious related adverse events reported.

Conclusion: In this *post hoc* analysis, on the first full day (24 hours) after administration of a single IV infusion, reductions in both the proportion of patients experiencing a migraine and the number of migraine hours experienced on that day were greater relative to baseline for patients receiving ALD403 (eptinezumab) compared to those receiving placebo. These observations suggest an early onset of migraine preventive efficacy, which may be related to IV administration, the unique pharmacokinetic and pharmacodynamic attributes of ALD403 (eptinezumab), the specific mechanism of action, or some combination of these attributes.

Disclosure of Interest

P. Goadsby Conflict with: Alder BioPharmaceuticals, J. Smith Conflict with: Alder BioPharmaceuticals, Conflict with: Alder BioPharmaceuticals, D. Dodick Conflict with: Alder BioPharmaceuticals, R. Lipton Conflict with: Alder BioPharmaceuticals, S. Silberstein Conflict with: Alder BioPharmaceuticals, R. Cady Conflict with: Alder BioPharmaceuticals, Conflict with: Alder BioPharmaceuticals, J. Hirman Conflict with: Alder BioPharmaceuticals

Neuromodulation for Headache

EP-01-020

Effect of cathodal transcranial direct current stimulation of the primary motor and sensory cortex on migraine

Mohammad Dawood Rahimi^{1*}, Javad Salehi Fadardi², Imanolla Bigdeli², Morteza Saeidi³, Mohammad Mahdi Ghasemi⁴ and Karim Nikkhah³

¹Ferdowsi University of Mashhad and Mashhad University of Medical Sciences, Herat, Afghanistan

²Psychology, Ferdowsi University

³Neurology

⁴Ear, Nose, and throat, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic Of

Objectives: Transcranial direct current stimulation is a novel technological method that has been used in the scope of pain related diseases like migraine-as a prevalent and high burden disease extensively. The aim of the present study was to evaluate the effectiveness of cathodal transcranial direct current stimulation (c-tDCS) over the right primary motor (M₁) and sensory (S₁) areas of the cortex on decreasing the intensity, duration, and frequency of pain in migraineurs.

Methods: This study was based on a randomized, double-blind, and sham-controlled design, and it tested 15 seasons (every week three seasons; over 5 consecutive weeks) of c-tDCS (20 min/1000µA) on forty-five migraineurs

(diagnosed according to the IHCID-II) into two experimental (nm = 15; ns = 15) and a control group (nc = 15).

Image:



Results: The results of a series of one-way ANOVA, c-tDCS showed significant ($p < 0.05$) reductions in all hypothesized aspects of pain in both experimental groups compared to the control one.

Conclusion: Therefore, it seems that c-tDCS can be used as a technological method in the treatment of migraine both therapeutically and prophylactically.

Disclosure of Interest

None Declared

Neuromodulation for Headache

EP-01-021

sTMS Blocks Cortical Spreading Depression by Suppressing Spontaneous Cortical Neuronal Firing and by Increasing the Threshold of Activation of the Occipital Cortex

J O. Lloyd^{1*}, B N. Okine¹, M G. Jones^{2,3}, G Lambrou^{1,4}, S B. McMahon², A P. Andreou^{1,4}; Headache group, Wolfson CARD

¹Headache Research-Wolfson CARD

²Neurorestoration Department-Wolfson CARD, King's College London

³Zenith Neurotech Ltd

⁴Headache Centre, Guy's and St Thomas' NHS Trust, London, United Kingdom

Objectives: Single-pulse transcranial magnetic stimulation (sTMS) is a non-invasive neuromodulation technique that has been shown to be a successful acute and preventative treatment for migraine patients with and without aura. *In vivo*, sTMS has been previously shown to block cortical spreading depression (CSD) and thalamic neuronal activity.